CervoMed Inc. filings document a clinical-stage biotechnology issuer focused on neflamapimod and age-related brain disorders. Form 8-K reports include Regulation FD disclosures, press release exhibits, operating and financial results, and updates on clinical studies such as RewinD-LB in dementia with Lewy bodies, pharmacokinetic work, biomarker analyses, and ALS platform inclusion.
Proxy materials describe shareholder voting matters, board and governance practices, executive compensation, equity awards, and related pay-versus-performance disclosures. The filing record also identifies CRVO common stock on the Nasdaq Capital Market and provides capital-structure, business-development, and financial-position disclosures relevant to CervoMed's drug-development model.
Woodline Partners LP, as investment adviser to Woodline Master Fund LP, reported beneficial ownership of common stock of CervoMed Inc.
Woodline Partners reported beneficial ownership of 688,987 shares of CervoMed common stock, representing 5.1% of the class, with sole voting and dispositive power over these shares. The percentage is based on 13,526,233 shares outstanding, as reported in a company prospectus filed on June 22, 2026, after completion of an offering.
Armistice Capital, LLC, together with Steven Boyd, reports beneficial ownership of 1,592,863 shares of CervoMed Inc. common stock, representing 9.53% of the class. All reported shares are held by Armistice Capital Master Fund Ltd., for which Armistice Capital serves as investment manager.
The reporting persons have shared voting and dispositive power over all 1,592,863 shares and no sole voting or dispositive power. Steven Boyd may be deemed to beneficially own these securities as managing member of Armistice Capital. The Master Fund has the right to receive dividends and sale proceeds from the reported securities and specifically disclaims beneficial ownership due to the Investment Management Agreement.
CervoMed Inc. reported second quarter 2026 results and development updates for neflamapimod, its lead drug for age-related brain disorders. The company highlighted plans to prioritize securing a strategic partnership to advance neflamapimod into a Phase 3 trial for dementia with Lewy bodies (DLB). Neflamapimod received an Innovation Passport Designation under the UK’s ILAP framework for DLB, and new analyses presented at AAIC 2026 reinforced its treatment effect in pure DLB and supported a 50 mg three-times-daily dose for the planned Phase 3 trial.
CervoMed completed two equity financings in June 2026 for aggregate gross proceeds of approximately $20.5 million. As of June 30, 2026, cash, cash equivalents and marketable securities were about $24.9 million, up from $20.9 million at year-end 2025, which the company believes will fund operations through the third quarter of 2027. For the quarter, there was no grant revenue versus $1.8 million a year earlier, R&D expenses were about $4.3 million, G&A expenses about $2.4 million, and net loss was roughly $6.6 million compared with $6.3 million in 2025.
CervoMed Inc. is a clinical-stage biotech developing neflamapimod for age‑related brain disorders, including dementia with Lewy bodies (DLB), nonfluent variant primary progressive aphasia, recovery after stroke and ALS. The drug targets p38α to reduce neuroinflammation and synaptic dysfunction.
For the quarter ended June 30, 2026, CervoMed reported a net loss of $6.6 million, and a first‑half 2026 net loss of $14.5 million, reflecting ongoing research and development and general and administrative spending without product revenue after NIA grant funding ended. Research and development expenses were $4.3 million in the quarter and $9.5 million year‑to‑date; general and administrative expenses were $2.4 million and $5.3 million, respectively.
In June 2026 the company completed a private placement and a registered direct offering, raising combined gross proceeds of about $20.5 million. Cash, cash equivalents and marketable securities totaled approximately $24.9 million at June 30, 2026. Management believes this will fund operations and capital needs through the third quarter of 2027 while it pursues a Phase 3 partnership in DLB.
CervoMed Inc. announced that its lead candidate neflamapimod has been granted an Innovation Passport, allowing entry into the United Kingdom’s Innovative Licensing and Access Pathway (ILAP) for development in dementia with Lewy bodies (DLB). ILAP is designed to accelerate time to market and facilitate patient access through coordinated input from the MHRA, NHS and health technology assessment bodies.
Neflamapimod is an oral small molecule that selectively inhibits the alpha isoform of p38 MAP kinase to target neuroinflammation and synaptic dysfunction. It has been generally well tolerated across more than 800 Phase 1 and 2 participants and showed consistent signals of efficacy in the 91-patient Phase 2a AscenD-LB and 159-patient Phase 2b RewinD-LB DLB trials, improving cognitive and functional outcomes and key neurodegeneration biomarkers, with greatest benefits in patients without Alzheimer’s co-pathology. CervoMed has obtained alignment with the FDA and global regulators on a potential registration path in DLB, is focused on identifying a strategic partner and funding for a Phase 3 DLB trial, and is advancing Phase 2a programs in nfvPPA and ALS.
CervoMed Inc. reported new clinical, biomarker, and imaging analyses for its lead candidate neflamapimod in dementia with Lewy bodies, based on the 159-patient Phase 2b RewinD-LB trial and an additional Phase 2 study.
Exploratory RewinD-LB analyses linked neflamapimod’s treatment effects on the CDR-SB scale to patients with low plasma pTau181 and to those achieving higher plasma drug exposure, including a capsule batch that showed 0.17 vs 0.95 CDR-SB worsening compared with prior placebo in the same participants. MRI data indicated durable slowing of right basal forebrain atrophy and increased connectivity with the default mode network during neflamapimod treatment.
A PK-PD review identified a ~4 ng/mL trough plasma threshold associated with clinical and biomarker improvements, informing selection of a planned 50 mg three-times-daily dose expected to reach that level in most patients. A separate 24-week Phase 2 trial of 80 mg twice daily in 26 dementia with Lewy bodies patients met its primary safety, tolerability, and pharmacokinetic objectives and showed encouraging secondary clinical findings. CervoMed also reiterated plans to advance neflamapimod into Phase 3 in dementia with Lewy bodies, seek a strategic partner, and deliver additional Phase 2a data in non-fluent variant primary progressive aphasia and amyotrophic lateral sclerosis in 2026.
CervoMed Inc. registered up to 10,081,131 shares of common stock for resale by existing investors, all tied to a June 11, 2026 private placement. The shares include stock already issued plus shares underlying Pre-Funded, Series B and Series C warrants. CervoMed will not receive proceeds from these resales but may receive up to approximately $1,593, $11.2 million and $10.6 million if the respective warrant series are exercised for cash, which would be used for working capital and general corporate purposes. A risk factor notes that resale of these shares, or the perception they may be sold, could pressure the market price. The company recently completed a $10.0 million registered direct offering and a $10.5 million private placement and obtained a US patent notice of allowance for neflamapimod in dementia with Lewy bodies.
CervoMed Inc. has completed enrollment in its Phase 2a clinical study of neflamapimod in nonfluent variant primary progressive aphasia (nfvPPA), a form of frontotemporal dementia with no approved treatments. The trial enrolled 25 participants on two oral dosing regimens over 24 weeks, followed by a 12‑week placebo‑controlled extension at leading U.S. academic centers.
Interim biomarker data from the study are scheduled to be presented at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston on November 16–19, 2026, with initial clinical data expected in the first quarter of 2027. Recent preclinical work published in Nature Neuroscience shows that p38α inhibition, including with neflamapimod, reversed axonal transport deficits in tau‑mutation FTD models, supporting the drug’s mechanistic rationale. Neflamapimod holds U.S. FDA Orphan Drug Designation for FTD, providing development and exclusivity benefits if approved.
CervoMed Inc shareholders were updated when Morgan Stanley and Morgan Stanley Capital Services LLC amended their Schedule 13G filings to report reduced holdings. Morgan Stanley reports 0.1% of the class with 10,000 shared voting power and 12,550 shared dispositive power; Morgan Stanley Capital Services LLC reports 0.0%.
The filing states both entities "have ceased to be the beneficial owner of more than five percent of the class of securities." The amendment is signed by an authorized signatory and includes exhibits for a joint filing agreement and Item 7 subsidiary details.